Jci_page_head_homepage_01 Jci_page_head_homepage_02
Scott J. Brodie, Bruce K. Patterson, Deborah A. Lewinsohn, Kurt Diem, David Spach, Phillip D. Greenberg, Stanley R. Riddell, Lawrence Corey
Published in Volume 105, Issue 10
J Clin Invest. 2000; 105(10):1407–1417 doi:10.1172/JCI8707
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

Analysis of PBMC for the in vivo persistence of neo-transduced CD8+ gag-specific T cells by TaqMan PCR. (a and b) Standard curves of neo and β-actin, respectively. Neo plasmid DNA (a) and genomic (PBMC) DNA (b) were diluted serially 1:5 before amplification with the appropriate primer sets. The β-actin standard curve was used to normalize the results obtained from patient PBMC to 1 μg of genomic DNA. (c) Serial 10-fold titration of neo-positive clones starting with an input ratio of 1 part neo DNA to 9 parts genomic DNA. Controls (ac) illustrate the linearity, sensitivity, and reproducibility of TaqMan PCR. (dh) The amount of neo present in recovered patient PBMC before, during, and after CTL infusions per microgram of CD8+ T-cell DNA. Parts dh represent patients 1–5, respectively. All figures show DNA concentration of the samples plotted verses threshold cycle (CT), and all time points represent the mean ± SEM of triplicate PCR amplifications. This assay is highly quantitative and capable of detecting ≤ 2 neo copies per 1 μg of PBMC DNA. Independent determinations of the frequency of neo-marked CD8+ cells in PBMC varied ≤ 0.2 log. Arrows indicate the day of T-cell infusions. AAn inguinal lymph node biopsy. All assays were repeated at least twice. Error bars are shown (some are not visible).